Variability in parathyroid hormone assays confounds clinical practice in chronic kidney disease patients

Annals of Clinical Biochemistry

Volumn 51, Issue 2, 2014, Pages 228-236

  Eddington, Helen ^a   Hudson, Julie E ^a   Oliver, Robert L ^a   Fraser, William D ^b   Hutchison, Alastair J ^c   Kalra, Philip A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

chronic kidney disease; clinical studies; haemodialysis; parathyroid hormone; PTH assay; Renal disease

Indexed keywords

CHRONIC KIDNEY DISEASE; CLINICAL STUDIES; HAEMODIALYSIS; PARATHYROID HORMONE; PTH ASSAY; RENAL DISEASE;

BLOOD CHEMICAL ANALYSIS; HUMANS; MEDICAL AUDIT; PARATHYROID HORMONE; REFERENCE STANDARDS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84898681778     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213491236     Document Type: Article

References (28)

1. Toussaint ND,Pedagogos E,Beavis J, et al.Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice.Nephrol Dial Transplant. 2011;26:1319-1326.
2. Almond A,Ellis AR,Walker SW.Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease.Ann Clin Biochem. 2012;49:63-67.
3. Joly D,Drueke TB,Alberti C, et al.Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study.Am J Kidney Dis. 2008;51:987-995.
4. Souberbielle JC,Boutten A,Carlier MC, et al.Inter-method variability in PTH measurement: implication for the care of CKD patients.Kidney Int. 2006;70:345-350.
5. Eknoyan G,Levin A,Levin N.W.National Kidney Foundation: K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease.Am J Kidney Dis. 2003;42:S1-S201.
6. Clinical practice guidelines. Module 2: complications. 2: complications, 4th ed. Hampshire, UK: Steddon S, Sharples E, 2007.Hampshire, UK: Steddon S, Sharples E; 2007:.
7. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).Kidney Int. 2009;76:S1-S130.
8. Holmes DT,Levin A,Forer B, et al.Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients.Clin Chem. 2005;51:915-917.
9. Tomaschitz A, Fahreleitner-Pammer A, Pieske Bet al.Effect of Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocrine disorders 2012.
10. Cantor T,Yang Z,Caraiani N, et al.Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions.Clin Chem. 2006;52:1771-1776.
11. Stokes FJ,Ivanov P,Bailey LM, et al.The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism.Clin Chem. 2011;57:138-140.
12. Monge M,Jean G,Bacri JL, et al.Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods.Clin Chem Lab Med. 2009;47:362-366.
13. Dawnay A,Farrington K,Castledine C, et al.UK Renal Registry 12th Annual Report (December 2009): chapter 10: biochemistry profile of patients receiving dialysis in the UK in 2008: national and centre-specific analyses.Nephron Clin Pract. 2010;115:c187-c237.
14. Gardham C,Stevens PE,Delaney MP, et al.Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.Clin J Am Soc Nephrol. 2010;5:1261-1267.
15. Souberbielle JC,Roth H,Fouque DP.Parathyroid hormone measurement in CKD.Kidney Int. 2010;77:93-100.
16. Divieti P,John MR,Juppner H, et al.Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor.Endocrinology. 2002;143:171-176.
17. Slatopolsky E,Finch J,Clay P, et al.A novel mechanism for skeletal resistance in uremia.Kidney Int. 2000;58:753-761.
18. Brossard JH,Lepage R,Cardinal H, et al.Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays.Clin Chem. 2000;46:697-703.
19. Vieira JG.PTH Assays: understanding what we have and forecasting what we will have.J Osteoporos. 2012;2012:523246-523246.
20. Coen G,Bonucci E,Ballanti P, et al.PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease.Am J Kidney Dis. 2002;40:348-354.
21. Herberth J,Branscum AJ,Mawad H, et al.Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.Am J Kidney Dis. 2010;55:897-906.
22. Monier-Faugere MC,Geng Z,Mawad H, et al.Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.Kidney Int. 2001;60:1460-1468.
23. Qi Q,Monier-Faugere MC,Geng Z, et al.Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis.Am J Kidney Dis. 1995;26:622-631.
24. Salusky IB,Goodman WG,Kuizon BD, et al.Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.Kidney Int. 2003;63:1801-1808.
25. Picton ML,Moore PR,Mawer EB, et al.Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure.Kidney Int. 2000;58:1440-1449.
26. Floege J,Kim J,Ireland E, et al.Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.Nephrol Dial Transplant. 2011;26:1948-1955.
27. Naves-Diaz M,Passlick-Deetjen J,Guinsburg A, et al.Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES study.Nephrol Dial Transplant. 2011;26:1938-1947.
28. Sturgeon CM,Sprague SM,Metcalfe W.Variation in parathyroid hormone immunoassay results - a critical governance issue in the management of chronic kidney disease.Nephrol Dial Transplant. 2011;26:3440-3445.